Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2021 - 2024)
Historic Other Non-Current Liabilities for Aligos Therapeutics (ALGS) over the last 4 years, with Q4 2024 value amounting to $72.4 million.
- Aligos Therapeutics' Other Non-Current Liabilities rose 16223.73% to $72.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $72.4 million, marking a year-over-year increase of 16223.73%. This contributed to the annual value of $72.4 million for FY2024, which is 16223.73% up from last year.
- Per Aligos Therapeutics' latest filing, its Other Non-Current Liabilities stood at $72.4 million for Q4 2024, which was up 16223.73% from $11.6 million recorded in Q3 2024.
- In the past 5 years, Aligos Therapeutics' Other Non-Current Liabilities registered a high of $72.4 million during Q4 2024, and its lowest value of $133000.0 during Q4 2021.
- In the last 4 years, Aligos Therapeutics' Other Non-Current Liabilities had a median value of $267000.0 in 2021 and averaged $13.9 million.
- In the last 5 years, Aligos Therapeutics' Other Non-Current Liabilities crashed by 5018.73% in 2022 and then surged by 16223.73% in 2024.
- Over the past 4 years, Aligos Therapeutics' Other Non-Current Liabilities (Quarter) stood at $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then surged by 20648.87% to $27.6 million in 2023, then soared by 162.24% to $72.4 million in 2024.
- Its Other Non-Current Liabilities stands at $72.4 million for Q4 2024, versus $11.6 million for Q3 2024 and $11.5 million for Q2 2024.